Bank of America Corp DE grew its position in shares of Oric Pharmaceuticals, Inc. (NASDAQ:ORIC - Free Report) by 105.5% in the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 1,043,159 shares of the company's stock after acquiring an additional 535,649 shares during the quarter. Bank of America Corp DE owned 1.01% of Oric Pharmaceuticals worth $13,217,000 at the end of the most recent reporting period.
Several other hedge funds also recently made changes to their positions in ORIC. Federation des caisses Desjardins du Quebec grew its position in shares of Oric Pharmaceuticals by 100.0% in the 4th quarter. Federation des caisses Desjardins du Quebec now owns 4,000 shares of the company's stock valued at $33,000 after acquiring an additional 2,000 shares during the period. Caitong International Asset Management Co. Ltd boosted its position in Oric Pharmaceuticals by 184.4% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 4,528 shares of the company's stock worth $37,000 after purchasing an additional 2,936 shares during the period. Mirae Asset Global Investments Co. Ltd. increased its holdings in shares of Oric Pharmaceuticals by 26.0% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,732 shares of the company's stock valued at $39,000 after purchasing an additional 977 shares during the last quarter. Russell Investments Group Ltd. acquired a new position in shares of Oric Pharmaceuticals in the third quarter valued at $60,000. Finally, CANADA LIFE ASSURANCE Co bought a new position in shares of Oric Pharmaceuticals in the third quarter valued at about $65,000. 95.05% of the stock is owned by institutional investors.
Oric Pharmaceuticals Price Performance
Shares of NASDAQ ORIC opened at $14.20 on Friday. The stock has a market capitalization of $1.47 billion, a PE ratio of -10.52 and a beta of 1.02. Oric Pharmaceuticals, Inc. has a one year low of $7.23 and a one year high of $14.93. The business's fifty day moving average price is $11.34 and its 200-day moving average price is $10.62.
Oric Pharmaceuticals (NASDAQ:ORIC - Get Free Report) last posted its quarterly earnings results on Monday, August 3rd. The company reported ($0.38) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.36) by ($0.02). As a group, equities analysts expect that Oric Pharmaceuticals, Inc. will post -1.53 EPS for the current fiscal year.
Analysts Set New Price Targets
Several analysts recently commented on the stock. Wall Street Zen raised shares of Oric Pharmaceuticals from a "strong sell" rating to a "sell" rating in a report on Saturday, July 25th. Stifel Nicolaus assumed coverage on shares of Oric Pharmaceuticals in a research report on Friday, June 12th. They set a "buy" rating and a $14.00 price objective for the company. The Goldman Sachs Group raised Oric Pharmaceuticals from a "neutral" rating to a "buy" rating and set a $15.00 price target for the company in a report on Friday, May 15th. Weiss Ratings reiterated a "sell (d-)" rating on shares of Oric Pharmaceuticals in a report on Friday, July 17th. Finally, Citigroup decreased their price target on Oric Pharmaceuticals from $17.00 to $16.00 and set a "buy" rating for the company in a report on Tuesday, May 5th. Thirteen analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus price target of $19.45.
Get Our Latest Stock Report on ORIC
About Oric Pharmaceuticals
(
Free Report)
Oric Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company headquartered in South San Francisco, California. The firm is dedicated to discovering and developing small molecule therapeutics designed to overcome resistance mechanisms in solid tumor oncology. Its research efforts focus on identifying novel targets and advancing precision medicines that can restore or enhance patient response when standard therapies fail.
The company's pipeline features lead candidates such as ORIC-101, a selective, orally available antagonist of the glucocorticoid receptor currently being evaluated in Phase 1/2 trials for patients with solid tumors who have acquired resistance to chemotherapy and hormonal agents.
Further Reading
Want to see what other hedge funds are holding ORIC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Oric Pharmaceuticals, Inc. (NASDAQ:ORIC - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider Oric Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Oric Pharmaceuticals wasn't on the list.
While Oric Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
